Enanta's RSV antiviral reduces viral load in phase 2 pediatric study

Enanta Pharmaceuticals’ respiratory syncytial virus (RSV) antiviral reduced the viral load in a phase 2 study in children, maintaining hopes the biotech can find a niche in a market now dominated by Big Pharma vaccines.